{
    "clinical_study": {
        "@rank": "121058", 
        "arm_group": [
            {
                "arm_group_label": "Alirocumab SAR236553 (REGN727)", 
                "arm_group_type": "Experimental", 
                "description": "Injection through subcutaneous (SC) administration"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Injection through subcutaneous (SC) administration"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To assess the effects of subcutaneous (SC) doses of alirocumab on the elimination (measured\n      by Fractional Clearance Rate (FCR)) of apolipoprotein B (apoB) in low density lipoprotein\n      (LDL) in adults with mildly elevated LDL-cholesterol (LDL-C).\n\n      Secondary Objectives:\n\n      To assess the effects of SC doses of alirocumab on:\n\n        -  Various parameters of  the metabolism and turnover in plasma of different lipoproteins\n\n        -  Plasma lipids concentration: total cholesterol, high density lipoprotein cholesterol\n           (HDL-C), triglycerides, low density lipoprotein cholesterol (LDL-C), apoB,\n           lipoprotein(a) (Lp(a))\n\n        -  Lipoprotein particle size profile\n\n        -  PCSK9 (free and total) concentrations in serum To assess safety and tolerability of\n           alirocumab. To assess emergence of anti-alirocumab antibodies. To document serum\n           alirocumab concentrations."
        }, 
        "brief_title": "Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "detailed_description": {
            "textblock": "Total duration of the study per subject is 26 weeks, including a screening period of \u2264 4\n      weeks, placebo treatment period of 4 weeks, alirocumab treatment period of 10 weeks, and a\n      follow up period of 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Generally healthy; LDL-C level in serum or plasma \u2265 100 mg/dL and < 190 mg/dL at\n        Screening.\n\n        Exclusion criteria:\n\n          -  LDL-C \u2265 160 mg/dL at Screening if more than 2 major Coronary Heart Disease risk\n             factors, as defined in National Cholesterol Education Program guidelines.\n\n          -  Receiving treatment of any kind for hyperlipidemia within 6 weeks of enrollment.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959971", 
            "org_study_id": "PDY13670", 
            "secondary_id": "U1111-1141-4567"
        }, 
        "intervention": [
            {
                "arm_group_label": "Alirocumab SAR236553 (REGN727)", 
                "description": "Pharmaceutical form:Solution for  injection Route of administration: Subcutaneous", 
                "intervention_name": "alirocumab SAR236553 (REGN727)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Pharmaceutical form:Solution for  injection Route of administration: Subcutaneous", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "Investigational Site Number 840001"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent change in Fractional Clearance Rate of apolipoprotein B (apoB) in Low Density Lipoproteins (pools/day) in plasma during alirocumab treatment", 
            "safety_issue": "No", 
            "time_frame": "baseline and at 12 days after last dose of alirocumab"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959971"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in lipids turnover parameters measured in isolated Very Low Density Lipoproteins (VLDL), Intermediate Density Lipoproteins (IDL), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL)", 
                "safety_issue": "No", 
                "time_frame": "baseline and at 12 days after last dose of alirocumab"
            }, 
            {
                "measure": "Change in post-heparin hepatic lipase and lipoprotein lipase activities", 
                "safety_issue": "No", 
                "time_frame": "baseline and at 2 days after last dose of alirocumab"
            }, 
            {
                "measure": "Change in lipids and apolipoproteins in plasma lipids panel", 
                "safety_issue": "No", 
                "time_frame": "baseline and at 2 days and at 11 days after last dose of alirocumab"
            }, 
            {
                "measure": "Assessment of Lipoprotein particle size profiles", 
                "safety_issue": "No", 
                "time_frame": "baseline and at 2 days and at 11 days after last dose of alirocumab"
            }, 
            {
                "measure": "Assessment of serum concentrations of PCSK9", 
                "safety_issue": "No", 
                "time_frame": "baseline and up to 2 weeks after last dose of alirocumab"
            }, 
            {
                "measure": "Assessment of safety parameters (clinical laboratory, ECG, vital signs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 10 weeks after last dose of alirocumab"
            }, 
            {
                "measure": "Assessment of the serum concentration of alirocumab SAR236553 (REGN727)", 
                "safety_issue": "No", 
                "time_frame": "baseline and up to 2 weeks after last dose of alirocumab"
            }, 
            {
                "measure": "Assessment of the serum concentration of anti-alirocumab SAR236553 (REGN727) antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and up to 10 weeks after last dose of alirocumab"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}